Myeloproliferative Neoplasm Quality of Life

~ International Study Group ~

For MPN-QOL Investigators

For MPN Healthcare Providers

Decrease Font Size
Increase Font Size

MEASURE Trial: MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation

Currently Enrolling

The MEASURE trial aims to assess the responsiveness of the MPN-SAF Diary to detect symptom change in MPN patients undergoing non-experimental medical therapy and/or phlebotomy.

To be eligible for this trial, patients must:

  1. Have either essential thrombocythemia, polycythemia vera, or myelofibrosis (primary and post polycythemia vera/post essential thrombocythemia).
  2. Patients must be beginning a new, non-experimental, therapeutic intervention for their MPN either medicinal (aspirin, hydroxyurea, anagrelide, interferon, busulfan, melphalan, cladribine, thalidomide, lenalidomide, prednisone, danazol, ruxolitinib) and/or phlebotomy.
  3. Patients must be willing to fill out the diary for 7 consecutive days (with at least the first daily assessment prior to therapy initiation) and then again for 7 consecutive days after a minimum of 90 days (maximum of 6 months). 


Login for Coinvestigators

Last Updated Thursday, July 18, 2019 - 05:53 PM.